ROSEN, NATIONAL TRIAL COUNSEL, Encourages Tandem Diabetes Care, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation - TNDM

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of misleading business information [1] Group 1: Legal Action and Investor Rights - Investors who purchased Tandem Diabetes Care securities may be entitled to compensation through a class action without any out-of-pocket fees [2] - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2] Group 2: Company Incident and Stock Impact - On August 7, 2025, Tandem Diabetes Care announced a voluntary medical device correction for select t:slim X2 insulin pumps due to a potential speaker-related issue, which led to a 19.9% drop in stock price on the same day [3] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked highly for settlements since 2013 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 [4]